Iovance Biotherapeutics (IOVA) Stock Forecast & Price Target

Iovance Biotherapeutics is viewed favorably because its commercial launch of Amtagvi is already translating into accelerating revenue, with 2Q26 total revenue of $99.3 million, up 66% year over year, and full-year 2026 guidance raised to $410-$420 million on sustained U.S. demand for AMTAGVI and Proleukin. The outlook is strengthened by an expanding treatment-center network of about 100 authorized centers, on track for at least 110 by YE26, along with in-house manufacturing and higher utilization that are improving gross margin to 56% and supporting better access and scalability. Its pipeline also offers multiple catalysts, including near-complete NSCLC enrollment with an update expected in 4Q26, a SARATOGA sarcoma program, and frontline melanoma data at ESMO, while approvals in Canada and Australia help validate the TIL platform and broaden commercial momentum.

Iovance Biotherapeutics is viewed cautiously because its value depends heavily on uncertain clinical and regulatory outcomes, with approval required from the FDA and foreign agencies and meaningful downside if trials are inconclusive or fail. Its commercial case also faces intense competitive pressure from approved melanoma agents and emerging solid-tumor CAR-T therapies, while the bear case assumes lifileucel’s uptake weakens and assigns only a 10% probability of commercial success. Although the company has a strong cash position, it spends heavily on R&D and may still need additional capital, creating financing risk alongside development and commercialization uncertainty.